Business
-
Johnson & Johnson has decided not to exercise an option acquired in a 2020 agreement with Pulmatrix for development and commercialization of Pulmatrix’s portfolio of inhaled narrow spectrum kinase inhibitors (NSKIs), including PUR1800. J&J’s Lung… Read more . . .
-
AIM ImmunoTech has announced that it will definitely advance an intranasal formulation of its Ampligen rintatolimod into a Phase 2 trial after the initial dose tested in a Phase 1 study showed no safety problems.… Read more . . .
-
Seelos Therapeutics has signed a strategic device partnership agreement with Aptar Pharma for the use of Aptar’s Bidose Liquid System (BDS) for Seelos’ SLS-002 intranasal ketamine, Seelos said. SLS-002 is in Phase 2 development for the… Read more . . .
-
According to United Therapeutics, the FDA has approved Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso has been approved for the treatment of pulmonary arterial hypertension… Read more . . .
-
According to Iconovo, Swedish immunotherapy developer Immune System Regulation (ISR) will pay up to 18.1 million Swedish kronor plus potential royalties for development of a dry powder COVID-19 vaccine delivered via Iconovo’s ICOone single dose… Read more . . .
-
Valeo Pharma has acquired the rights to commercialize Novartis’ Enerzair Breezhaler indacaterol / glycopyrronium / mometasone furoate and Atectura Breezhaler indacaterol / mometasone furoate) DPIs in Canada, the company said. Terms of the deal were not announced. Valeo CEO… Read more . . .
-
Dutch startup Leyden Laboratories, which has formed to develop intranasal vaccines, has closed a €40 Million Series A financing led by GV (formerly known as Google Ventures), the company said. Leyden Labs was founded by… Read more . . .
-
Starpharma has announced the signing of a UK sales and distribution agreement for its Viraleze astodrimer sodium antiviral nasal spray with LloydsPharmacy and its parent company McKesson, with LloydsPharmacy set to launch the nasal spray… Read more . . .
-
Sino Biopharmaceutical Limited will pay $110 million up front in addition to a share of profits for Belgian soft mist inhaler developer Softhale. According to New Rhein, the fund’s investments to acquire a 60% stake in Softhale were… Read more . . .
-
Bausch Health has acquired the rights to commercialize Glenmark’s Ryaltris olopatadine / mometasone furoate nasal spray in Canada, Glenmark has announced. According to Glenmark, which is responsible for regulatory approval under the agreement with Bausch,… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland